Patents by Inventor Li-Xin Zhu

Li-Xin Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS
    Publication number: 20110293656
    Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.
    Type: Application
    Filed: May 18, 2011
    Publication date: December 1, 2011
    Inventors: Gerd Sutter, Volker Erfle, Caroline Staib, Yuan Wang, Guangdi Li, Li-Xin Zhu
  • RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS
    Publication number: 20090238843
    Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.
    Type: Application
    Filed: June 2, 2009
    Publication date: September 24, 2009
    Inventors: Gerd Sutter, Volker Erfle, Caroline Staib, Yuan Wang, Guangdi Li, Li-Xin Zhu
  • Recombinant mva capable of expressing structural hcv antigens
    Publication number: 20050019347
    Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.
    Type: Application
    Filed: September 5, 2002
    Publication date: January 27, 2005
    Inventors: Gerd Sutter, Volker Erfle, Yuan Wang, Guangdi Li, Li-Xin Zhu, Caroline Staib